ADRO Aduro Biotech Inc.

+0.03  (+2%)
Previous Close 1.35
Open 1.35
Price To Book 1.09
Market Cap 110,593,578
Shares 80,140,274
Volume 280,322
Short Ratio
Av. Daily Volume 435,423

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Initial data at SITC November 2018 noted 2/40 PRs and 11 with SD.
Solid tumors or lymphomas
Phase 2b primary endpoint not met - May 2016
CRS-207 and GVAX Pancreas - ECLIPSE trial
Pancreatic cancer
Partial clinical hold announced October 24, 2016. Hold released November 21, 2016.
CRS-207 and GVAX Pancreas and nivolumab - STELLAR trial
Pancreatic cancer
Noted December 12, 2017 that development to be discontinued.
CRS-207 with pembrolizumab
Mesothelioma - cancer
Phase 1 ongoing.
Colorectal Cancer
Phase 1 ongoing.
Colorectal Cancer
Phase 1b initiation announced June 7, 2018.
ADU-214 with Nivolumab
Non-Small Cell Lung Cancer
Phase 1b presentation at ASCO June 2, 2019 noted 1 CR and 2/8 PRs among TNBC patients. 2/25 PRs among melanoma patients.
ADU-S100 and Spartalizumab
Solid tumors or lymphomas
Phase 1 commencement of dosing announced February 11, 2019.
ADU-S100 and ipilimumab
Phase 1 initial data in healthy volunteers expected in 1H 2020 and IgAN patients in 2H 2020.
IgA Nephropathy

Latest News

  1. Who Has Been Selling Aduro BioTech, Inc. (NASDAQ:ADRO) Shares?
  2. Aduro (ADRO) Earnings Miss in Q2, Revenues Meet Estimates
  3. Aduro Biotech Provides Business Update and Reports Second Quarter 2019 Financial Results
  4. Aduro Biotech (ADRO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
  5. AbbVie (ABBV) Acquires Mavupharma to Boost Cancer Portfolio
  6. Aduro Stock Crashes After ASCO Updates on Cancer Candidate
  7. Aduro Biotech and Novartis Present Results from Ongoing Phase 1b Study of STING Agonist ADU-S100 (MIW815) in Combination with Anti-PD-1 Monoclonal Antibody Spartalizumab (PDR001) in Patients with Advanced Solid Tumors or Lymphomas
  8. Health Care Digest: Cancer's show-and-tell meeting, a new biotech building rises and lupus patients' plea
  9. Aduro Biotech to Host Investor Event Featuring ADU-S100 (MIW815) Clinical Data Presented at the 2019 American Society of Clinical Oncology Annual Meeting
  10. Aduro Biotech Announces Clinical Program Update for Anti-APRIL Antibody BION-1301
  11. Aduro (ADRO) Q1 Earnings and Revenues Fall Shy of Estimates
  12. Aduro Biotech (ADRO) Reports Q1 Loss, Misses Revenue Estimates
  13. What's in Store for Axsome (AXSM) This Earnings Season?
  14. Aduro Biotech Reports First Quarter 2019 Financial Results
  15. Guardant Health (GH) to Report Q1 Earnings: What's in Store?
  16. Proteostasis (PTI) to Post Q1 Earnings: What's in Store?
  17. Soleno Therapeutics (SLNO) to Post Q1 Earnings: What's Up?
  18. What's in the Cards for Perrigo (PRGO) This Earnings Season?
  19. Assertio Therapeutics (ASRT) to Post Q1 Earnings: What's Up?
  20. Mylan (MYL) to Report Q1 Earnings: What's in the Offing?